Walleye Capital’s Pacific Biosciences PACB Stock Holding History

Walleye Capital’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-40,200	Closed	-$55.1K	–	5726
2024 Q2	$55.1K	Sell	40,200 -11,200	-22%	-$22.6K	﹤0.01%	4901
2024 Q1	$193K	Buy	51,400 +36,200	+238%	+$212K	﹤0.01%	4000
2023 Q4	$149K	Buy	15,200 +1,400	+10%	+$11.4K	﹤0.01%	3841
2023 Q3	$115K	Sell	13,800 -16,000	-54%	-$183K	﹤0.01%	3877
2023 Q2	$396K	Buy	29,800 +6,300	+27%	+$76.6K	﹤0.01%	2607
2023 Q1	$272K	Buy	+23,500	New	+$234K	﹤0.01%	2204

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Walleye Capital's PACB Position: Q1 2025 in Review

Walleye Capital sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 1,943,046 shares — an estimated $3.56M sold.

Walleye Capital first reported a position in PACB in Q2 2020 and held it in 10 quarters. The position peaked at $3.56M in Q4 2024. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

Walleye Capital reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 1,943,046 Pacific Biosciences shares in Q1 2025, an estimated $3.56M.
Walleye Capital first reported a position in Pacific Biosciences in Q2 2020 and held it in 10 quarters.
Walleye Capital's Pacific Biosciences position peaked at $3.56M in Q4 2024.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.